Cancer may lurk in 'normal looking' skin
Medical Xpress
MAY 11, 2023
A University of Queensland study has found skin with few visible freckles or blemishes may still carry sun-damaged DNA mutations that can trigger cancer.
126 
Leading innovators in anti-influenza antibody compositions for the pharmaceutical industry
Pharmaceutical Technology
MAY 8, 2023
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.
Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Leading innovators in anti-viral antigen-based compositions for the pharmaceutical industry
Pharmaceutical Technology
MAY 8, 2023
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.
Gene-based blood test for melanoma spread evaluates treatment progress
Scienmag
FEBRUARY 12, 2021
A test that monitors blood levels of DNA fragments released by dying tumor cells may serve as an accurate early indicator of treatment success in people in late stages of one of the most aggressive forms of skin cancer, a new study finds. Led by NYU Grossman School of Medicine and Perlmutter Cancer Center researchers, […].
Even Winter Carries Skin Cancer Risks for College Students
The Pharma Data
DECEMBER 24, 2020
It penetrates through glass and clouds, damaging the cell’s DNA and aging skin.” The findings were recently published in the Journal of the Dermatology Nurses’ Association. . “Tanning beds are very purposefully exposing your skin to potential cancer,” Merrill said. © 2020 HealthDay. All rights reserved.
Eflornithine (Iwilfin) Finally Gets Approval in a Cancer Indication with FDA Nod for High-Risk Neuroblastoma
XTalks
DECEMBER 14, 2023
However, its uses expanded over the years into other indications, ranging from parasitic infection to dermatology. The drug was initially developed for treating cancer, particularly cancers like colon cancer. The disease is aggressive and difficult to treat with limited treatment options.
GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumours
The Pharma Data
AUGUST 17, 2021
Mismatch repair-deficient tumours contain abnormalities that affect the proper repair of DNA when copied in a cell [i]. About Mismatch Repair Deficiency In normal cells, mismatch repair (MMR) is a process that corrects errors introduced during DNA replication via enzymes. Immune-Mediated Dermatologic Adverse Reactions.
Let's personalize your content